Reported about 1 year ago
Biotech stocks can offer high returns, but also come with high risks due to long lead times, overhead costs, and regulatory uncertainties. TipRanks identifies two biotech companies with imminent FDA decisions: Ascendis Pharma, awaiting approval for its PTH drug, and Citius Pharmaceuticals, focusing on treatments for critical care conditions like lymphoma. Analysts foresee significant upside potential for both stocks due to upcoming catalysts and innovative drug pipelines.
Source: YAHOO